Analysis reports high concordance of HER2 immunohistochemistry in endometrial carcinoma, suggesting DNA expression aids in tumor classification.
Breast and gastric scoring criteria show high concordance in endometrial carcinoma, with discordance primarily in equivocal tumors. RNA expression may help stratify equivocal from negative cases. Further study is needed to determine whether HER2 alterations at the DNA, RNA, or protein level predict response to newer generation HER2-targeted therapies.
No takes yet. Share an insight, caveat, or question.
Furuya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: